// App-Quantinova.ai

P746 : Living with ulcerative colitis in Germany: quantifying the socioeconomic impact of moderate to severe ulcerative colitis

Researchers

Presenter

  • A Dignass

Principal Investigators

  • J Waller

  • J C Cappelleri

  • L Salese

  • A Kisser

  • L Dietz

  • M DiBonaventura

  • R Wood

  • D Bargo

Medical Centers

  • Agaplesion Markus Hospital, Frankfurt, Germany

  • Adelphi Real-World, Bollington, UK

  • Pfizer, Groton, CT

  • Pfizer Inc, Collegeville, PA

  • Pfizer Pharma GmbH, Berlin, Germany

  • Pfizer Inc, New York, NY

Locations

  • Germany

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Autoimmune (AI)

  • Genetic Disorder

  • Gastroenterology (GU)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

  • Adalimumab

  • Infliximab

  • golimumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved